VanEck Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.7M | Sell |
69,482
-19,577
| -22% | -$2.9M | 0.01% | 583 |
|
|
2026
Q1 | $11.7M | Buy |
89,059
+3,931
| +5% | +$522K | 0.01% | 549 |
|
|
2025
Q4 | $12.1M | Sell |
85,128
-9,969
| -10% | -$1.44M | 0.01% | 504 |
|
|
2025
Q3 | $13.3M | Sell |
95,097
-12,757
| -12% | -$1.73M | 0.01% | 455 |
|
|
2025
Q2 | $13.6M | Buy |
107,854
+18,775
| +21% | +$2.15M | 0.02% | 407 |
|
|
2025
Q1 | $9.85M | Sell |
89,079
-4,327
| -5% | -$548K | 0.01% | 484 |
|
|
2024
Q4 | $12.8M | Buy |
93,406
+9,824
| +12% | +$1.22M | 0.02% | 405 |
|
|
2024
Q3 | $9.62M | Sell |
83,582
-12,637
| -13% | -$1.73M | 0.01% | 454 |
|
|
2024
Q2 | $13.2M | Buy |
96,219
+3,976
| +4% | +$545K | 0.02% | 356 |
|
|
2024
Q1 | $12.7M | Buy |
92,243
+85,772
| +1,325% | +$11.7M | 0.02% | 350 |
|
|
2023
Q4 | $853K | Sell |
6,471
-1,098
| -15% | -$126K | ﹤0.01% | 985 |
|
|
2023
Q3 | $852K | Sell |
7,569
-1,479
| -16% | -$156K | ﹤0.01% | 935 |
|
|
2023
Q2 | $853K | Sell |
9,048
-938
| -9% | -$91.7K | ﹤0.01% | 903 |
|
|
2023
Q1 | $1.01M | Buy |
+9,986
| New | +$1.04M | ﹤0.01% | 834 |
|
|
2021
Q3 | – | Sell |
-113,390
| Closed | -$11M | – | 1313 |
|
|
2021
Q2 | $11M | Buy |
113,390
+8,838
| +8% | +$847K | 0.03% | 334 |
|
|
2021
Q1 | $10.2M | Buy |
104,552
+530
| +0.5% | +$55.6K | 0.03% | 340 |
|
|
2020
Q4 | $9.97M | Buy |
104,022
+16,789
| +19% | +$1.62M | 0.03% | 310 |
|
|
2020
Q3 | $8.39M | Sell |
87,233
-9,870
| -10% | -$1.14M | 0.03% | 284 |
|
|
2020
Q2 | $11.8M | Buy |
97,103
+24,354
| +33% | +$2.69M | 0.04% | 235 |
|
|
2020
Q1 | $6.3M | Sell |
72,749
-31,139
| -30% | -$3.05M | 0.03% | 278 |
|
|
2019
Q4 | $11.2M | Buy |
103,888
+136
| +0.1% | +$14.2K | 0.04% | 242 |
|
|
2019
Q3 | $9.35M | Buy |
103,752
+1,469
| +1% | +$137K | 0.04% | 225 |
|
|
2019
Q2 | $8.64M | Sell |
102,283
-11,483
| -10% | -$943K | 0.04% | 242 |
|
|
2019
Q1 | $10M | Sell |
113,766
-6,963
| -6% | -$582K | 0.05% | 214 |
|
|
2018
Q4 | $8.62M | Sell |
120,729
-865
| -0.7% | -$82.9K | 0.04% | 237 |
|
|
2018
Q3 | $14.9M | Sell |
121,594
-1,948
| -2% | -$221K | 0.07% | 208 |
|
|
2018
Q2 | $12.1M | Buy |
123,542
+19,302
| +19% | +$1.73M | 0.06% | 220 |
|
|
2018
Q1 | $8.64M | Sell |
104,240
-25,155
| -19% | -$2.12M | 0.04% | 241 |
|
|
2017
Q4 | $10M | Sell |
129,395
-142,977
| -52% | -$9.75M | 0.05% | 227 |
|
|
2017
Q3 | $16.7M | Buy |
272,372
+55,810
| +26% | +$2.94M | 0.09% | 188 |
|
|
2017
Q2 | $9.96M | Buy |
216,562
+40,186
| +23% | +$1.95M | 0.05% | 230 |
|
|
2017
Q1 | $7.64M | Buy |
176,376
+10,002
| +6% | +$429K | 0.03% | 254 |
|
|
2016
Q4 | $6.44M | Buy |
166,374
+6,072
| +4% | +$275K | 0.03% | 258 |
|
|
2016
Q3 | $8.12M | Sell |
160,302
-28,870
| -15% | -$1.44M | 0.04% | 235 |
|
|
2016
Q2 | $8.6M | Buy |
+189,172
| New | +$8.71M | 0.04% | 211 |
|
Other funds holding NBIX
VanEck Associates's NBIX Position: Q2 2026 in Review
VanEck Associates reduced its Neurocrine Biosciences (NBIX) stake by 22% in Q2 2026, selling an estimated $2.9M and leaving 69,482 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #583.
VanEck Associates first reported a position in NBIX in Q2 2016 and has held it in 35 quarters since. The position peaked at $16.7M in Q3 2017. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- VanEck Associates held 69,482 shares of Neurocrine Biosciences worth $11.7M as of Q2 2026.
- VanEck Associates sold 19,577 Neurocrine Biosciences shares in Q2 2026, an estimated $2.9M.
- Neurocrine Biosciences made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #583 holding.
- VanEck Associates first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 35 quarters since.
- VanEck Associates's Neurocrine Biosciences position peaked at $16.7M in Q3 2017.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.